AR069041A1 - Compuestos de oxadiazolidinadiona agonistas de receptores gpr40, composiciones farmaceuticas que los contienen y usos, como secretagogos de insulina, en el tratamiento y/o prevencion de la diabetes mellitus - Google Patents
Compuestos de oxadiazolidinadiona agonistas de receptores gpr40, composiciones farmaceuticas que los contienen y usos, como secretagogos de insulina, en el tratamiento y/o prevencion de la diabetes mellitusInfo
- Publication number
- AR069041A1 AR069041A1 ARP080104665A ARP080104665A AR069041A1 AR 069041 A1 AR069041 A1 AR 069041A1 AR P080104665 A ARP080104665 A AR P080104665A AR P080104665 A ARP080104665 A AR P080104665A AR 069041 A1 AR069041 A1 AR 069041A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- substituted
- secretagogs
- oxadiazolidinadiona
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Compuesto de fórmula (1), en la que los símbolos tienen los significados siguientes: L¹ y L³ son iguales o diferentes entre sí y cada uno representa CH o N; L² representa O ó NH; R¹ representa -H o alquilo C₁₋₆; R² representa un grupo de fórmula (2) ó (3); L⁴ representa CH o N; A y B son iguales o diferentes entre sí y representan -O-(alquilo C₁₋₆ sustituido con uno o más grupo(s) seleccionado(s) del grupo G¹), amino que puede estar sustituido con uno o más grupo(s) seleccionado(s) del grupo G², -H o R³ (siempre que al menos uno de A y B representa un grupo distinto de -H y -R³); R³ es igual o diferente entre sí y representa alquilo C₁₋₆ que puede estar sustituido con uno o más grupo(s) seleccionado(s) del grupo que consiste en -OH y halógeno, halógeno o -O-alquilo C₁₋₆; R⁴ representa alquilo C₁₋₆ que está sustituido con uno o más grupo(s) seleccionado(s) del grupo G¹; n representa 1 ó 2; grupo G¹ representa el grupo que consiste en -NHCO₂RZ, -NH₂, -NHCORZ, -NHCO-cicloalquilo, -NHCO-arilo, -NHSO₂RZ, 1,3-dioxolan-4-ilo que puede estar sustituido con de 1 a 5 alquilo C₁₋₆, -OH, -OCORZ, -ORZ, -CO₂RZ, -CO₂H, -CONHRZ y CON(RZ)₂; el grupo G² representa el grupo que consiste en CO₂RZ y -RZ; y RZ es igual o diferente entre sí y representa alquilo C₁₋₆ que puede estar sustituido con uno o más grupo(s) seleccionado(s) del grupo que consiste en -OH y -OCO-alquilo C₁₋₆; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007275840 | 2007-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069041A1 true AR069041A1 (es) | 2009-12-23 |
Family
ID=40579527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080104665A AR069041A1 (es) | 2007-10-24 | 2008-10-24 | Compuestos de oxadiazolidinadiona agonistas de receptores gpr40, composiciones farmaceuticas que los contienen y usos, como secretagogos de insulina, en el tratamiento y/o prevencion de la diabetes mellitus |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100267775A1 (es) |
EP (1) | EP2216330A4 (es) |
JP (1) | JPWO2009054423A1 (es) |
KR (1) | KR20100075539A (es) |
CN (1) | CN101835763A (es) |
AR (1) | AR069041A1 (es) |
AU (1) | AU2008314963A1 (es) |
CA (1) | CA2703793A1 (es) |
IL (1) | IL205066A0 (es) |
MX (1) | MX2010004503A (es) |
NZ (1) | NZ584811A (es) |
RU (1) | RU2010120681A (es) |
SA (1) | SA08290669B1 (es) |
TW (1) | TW200932219A (es) |
WO (1) | WO2009054423A1 (es) |
ZA (1) | ZA201002605B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
JPWO2011052756A1 (ja) | 2009-10-30 | 2013-03-21 | 持田製薬株式会社 | 新規3−ヒドロキシ−5−アリールイソキサゾール誘導体 |
CA2785674A1 (en) | 2009-12-25 | 2011-06-30 | Mochida Pharmaceutical Co., Ltd. | Novel 3-hydroxy-5-arylisothiazole derivative |
US9040525B2 (en) | 2010-10-08 | 2015-05-26 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
JP5420796B2 (ja) | 2011-04-27 | 2014-02-19 | 持田製薬株式会社 | 新規3−ヒドロキシイソチアゾール1−オキシド誘導体 |
AU2012248627A1 (en) | 2011-04-28 | 2013-11-14 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
CN104780915A (zh) | 2012-07-11 | 2015-07-15 | 埃尔舍利克斯治疗公司 | 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物 |
AU2014315457B2 (en) | 2013-09-04 | 2018-05-10 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
KR20160077213A (ko) | 2013-11-14 | 2016-07-01 | 카딜라 핼쓰캐어 리미티드 | 새로운 헤테로시클릭 화합물 |
US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
SG11201804152RA (en) | 2015-11-19 | 2018-06-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
ES2844374T3 (es) | 2015-12-22 | 2021-07-22 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
EP3452476B1 (en) | 2016-05-06 | 2021-12-15 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
ES2927984T3 (es) | 2016-06-20 | 2022-11-14 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US10144706B2 (en) * | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
EP3558985B1 (en) | 2016-12-22 | 2022-09-07 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MX2019007651A (es) | 2016-12-22 | 2020-02-07 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion de ligando 1 de muerte programada (pd-l1). |
CN108003074B (zh) * | 2017-12-21 | 2019-07-05 | 四川大学华西医院 | 联苯羧酸类化合物及其制备方法和用途 |
CN111683660A (zh) * | 2018-02-05 | 2020-09-18 | 斯特拉斯堡大学 | 用于治疗疼痛的化合物和组合物 |
MX2020010321A (es) | 2018-03-30 | 2021-01-08 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
DK3790877T3 (da) | 2018-05-11 | 2023-04-24 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer |
WO2020104578A2 (en) * | 2018-11-21 | 2020-05-28 | University Of Copenhagen | Modulators of free fatty acid receptor 1 and their use for treatment of diseases |
EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
CA3155852A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS |
WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
MX2022005651A (es) | 2019-11-11 | 2022-07-27 | Incyte Corp | Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1). |
UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
JP2023548859A (ja) | 2020-11-06 | 2023-11-21 | インサイト・コーポレイション | Pd-1/pd-l1阻害剤ならびにその塩及び結晶形態を作製するためのプロセス |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW268952B (es) * | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
JPH072848A (ja) | 1993-04-23 | 1995-01-06 | Sankyo Co Ltd | モルホリンおよびチオモルホリン誘導体 |
CA2160989A1 (en) * | 1993-04-30 | 1994-11-10 | Kunihiro Niigata | Novel bisoxadiazolidine derivative |
JP3762607B2 (ja) | 1993-08-09 | 2006-04-05 | 武田薬品工業株式会社 | 2,4−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物 |
US5480896A (en) * | 1994-01-27 | 1996-01-02 | American Home Products Corporation | Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents |
US5420146A (en) | 1994-05-10 | 1995-05-30 | American Home Products Corporation | Di-oxadiazolidine derivatives as antihyperglycemic agents |
ES2199366T3 (es) | 1996-12-31 | 2004-02-16 | Dr. Reddy's Laboratories Ltd. | Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas. |
AU2003277576A1 (en) * | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
CA2527691C (en) * | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
JP4074616B2 (ja) * | 2003-12-25 | 2008-04-09 | 武田薬品工業株式会社 | 3−(4−ベンジルオキシフェニル)プロパン酸誘導体 |
US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
EP1698624B1 (en) | 2003-12-26 | 2012-06-27 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
EP1726580A4 (en) | 2004-03-15 | 2008-02-13 | Takeda Pharmaceutical | AMINOPHNYLPROPANO ACID DERIVATIVE |
TW200815377A (en) * | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
-
2008
- 2008-10-20 TW TW097140166A patent/TW200932219A/zh unknown
- 2008-10-22 AU AU2008314963A patent/AU2008314963A1/en not_active Abandoned
- 2008-10-22 NZ NZ584811A patent/NZ584811A/en not_active IP Right Cessation
- 2008-10-22 CA CA2703793A patent/CA2703793A1/en not_active Abandoned
- 2008-10-22 JP JP2009538239A patent/JPWO2009054423A1/ja not_active Withdrawn
- 2008-10-22 EP EP08842584A patent/EP2216330A4/en not_active Withdrawn
- 2008-10-22 CN CN200880113158A patent/CN101835763A/zh active Pending
- 2008-10-22 WO PCT/JP2008/069164 patent/WO2009054423A1/ja active Application Filing
- 2008-10-22 KR KR1020107008901A patent/KR20100075539A/ko not_active Application Discontinuation
- 2008-10-22 RU RU2010120681/04A patent/RU2010120681A/ru not_active Application Discontinuation
- 2008-10-22 SA SA8290669A patent/SA08290669B1/ar unknown
- 2008-10-22 US US12/739,501 patent/US20100267775A1/en not_active Abandoned
- 2008-10-22 MX MX2010004503A patent/MX2010004503A/es not_active Application Discontinuation
- 2008-10-24 AR ARP080104665A patent/AR069041A1/es unknown
-
2010
- 2010-04-14 ZA ZA2010/02605A patent/ZA201002605B/en unknown
- 2010-04-14 IL IL205066A patent/IL205066A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20100075539A (ko) | 2010-07-02 |
JPWO2009054423A1 (ja) | 2011-03-03 |
SA08290669B1 (ar) | 2011-07-20 |
NZ584811A (en) | 2011-06-30 |
ZA201002605B (en) | 2011-06-29 |
RU2010120681A (ru) | 2011-11-27 |
IL205066A0 (en) | 2010-11-30 |
CN101835763A (zh) | 2010-09-15 |
WO2009054423A1 (ja) | 2009-04-30 |
CA2703793A1 (en) | 2009-04-30 |
EP2216330A1 (en) | 2010-08-11 |
MX2010004503A (es) | 2010-07-06 |
TW200932219A (en) | 2009-08-01 |
US20100267775A1 (en) | 2010-10-21 |
AU2008314963A1 (en) | 2009-04-30 |
EP2216330A4 (en) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069041A1 (es) | Compuestos de oxadiazolidinadiona agonistas de receptores gpr40, composiciones farmaceuticas que los contienen y usos, como secretagogos de insulina, en el tratamiento y/o prevencion de la diabetes mellitus | |
AR092503A1 (es) | 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b | |
PE20080069A1 (es) | Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40) | |
AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR064049A1 (es) | Derivados de acidos carboxilicos unidos a heterociclos, composiciones farmaceuticas que los contienen, y usos como promotores de la secrecion de insulina en el tratamiento de la diabetes mellitus. | |
ECSP067079A (es) | Derivados de ácido carboxílico de bencimidazolona | |
PE20091425A1 (es) | Derivados de aminotiazol | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
UY29184A1 (es) | Derivados de sulfonilbencimidazol | |
UY32884A (es) | 1-sustituido-4-(5-(fenil o heteroaril)metoxi)-pirimidin-2-il)piperazinas y piperidinas | |
BRPI0911035A2 (pt) | ativadores de pirrolidinona glicoquinase | |
ECSP099638A (es) | Nuevo compuesto de adenina | |
AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
CO6400139A2 (es) | Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica | |
PE20090888A1 (es) | Compuestos heterociclicos como agentes moduladores del receptor acoplado a la proteina g gpr119 | |
ES2620531T3 (es) | Inhibidores de la fosfodiesterasa tipo 10A | |
AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
UY29389A1 (es) | Derivados sustituidos del ácido1-((4-((((3,3-dimetil-2-oxo-2,3-dihidro-1h-indol-1-il)carbonil)amino)metil)piperidin-1-il)metil)ciclobutanocarboxílico, sales farmaceuticamente aceptables, composiciones que los contienen y aplicaciones. | |
AR092827A1 (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas | |
AR076228A1 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
AR088857A1 (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas | |
AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
AR092684A1 (es) | Compuestos de sulfonamida sustituidos | |
AR075582A1 (es) | Compuestos de 4- isopropilfenilglucitol | |
PE20060640A1 (es) | Derivados del acido alcanoico arilcicloalquil-sustituidos y procedimientos para su preparacion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |